Late-stage results Otsuka presented in IgA nephropathy triggered a sell-off in Vera shares. Elsewhere, investors scrutinized ...

The acquisition includes a rare immunology disease medicine and an advanced and early-stage immunology pipeline.

Sanofi announced that it will buy pharma company Blueprint Medicines for $129 per share, making the deal worth more than $9 ...

MoonLake jumps 18% after a report says MRK made a $3 billion-plus offer earlier this year, with talks potentially set to resume.

Regeneron licensed a weight loss drug and revealed study data for a pair of muscle-preserving medicines. Elsewhere, two neuroscience biotechs cut deals and Bluebird officially went private.

Jefferies has predicted more small tuck-in deals to come, as biotechs struggle to access capital despite key clinical ...

Sanofi is set to acquire Blueprint Medicines, a US-based biopharmaceutical company specialising in systemic mastocytosis.

A French pharmaceutical giant is acquiring a biotech and its rare immunology disease treatment which is already approved in ...

Blueprint Medicines came under pressure from Wall Street on Monday after at least six brokerages downgraded the stock ...

Sanofi to acquire Blueprint Medicines for up to $9.5B to expand its rare immunological disease portfolio, including an ...

The French drugmaker has acquired Blueprint Medicines Corporation following its sale of health consumer brand Opella.